May 5, 2016

Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

July 2, 2015

Accera Hoping for an Alzheimer’s Breakthrough

June 24, 2015

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

May 27, 2021

Interview: Cerecin’s company progress and expansion into migraine and infantile spasms

February 1, 2019

Interview: AD is the largest unmet clinical need

October 24, 2018

Interview: Brains and medicine

Application of FibroScan for hepatic safety monitoring in early clinical studies

Sabina Paglialunga, PhD, Terry O’Reilly, MD CPI, Samuel Henderson, PhD, Bruce H Morimoto, PhD, Lilian Chow, MRDM, Nor Rahimah binte Ramli, Lars Nelleman, MD, Judith Walker, MD 2021 ACCP Virtual Annual Meeting

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Bruce Morimoto, PhD Clinical Trials on Alzheimer’s Disease 2020

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese

Bruce H. Morimoto, PhD; Lilian Chow, MRDM; Lars Nelleman,MD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD

Judith Anne Walker, MD; Lars Nelleman,MD; Bruce H Morimoto, PhD; Lilian Chow, MRDM Clinical Trials on Alzheimer’s Disease 2020

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID

Lilian Chow, MRDM; Lars Nelleman, MD; Bruce H. Morimoto, PhD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

Development of tricaprilin, a ketogenic drug for Alzheimer's disease

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Samuel T Henderson, PhD Alzheimer's Association International Conference 2020